In fact, of the over 3324 AMPs found and studied, many are not suitable for pharmacological application in their natural state and very few are EMA- and FDA-approved for AD-related applications as most AMPs lack fundamental information, such as pharmacokinetic information and significant information regarding their potential secondary effects [63,153]. This evidence concerns the gene ADSL and Alzheimer disease.